Diagnostics companies have had record fundraising on the public markets over the past few years. Venture capital also expanded last year, raising more than double than in previous years, with $113 million the average quarterly amount raised over the past year compared with only $47 million for a quarter in previous years. Investors seem to be taking seriously expectations that innovations in molecular diagnostics and pharmacogenomics will lead to a rapidly expanding diagnostics market around 2010.
Source: Kalorama Information
Source: Kalorama Information
Source: Figure based on 2004 financial reports, Burrill & Company
Source: BioCentury
Source: BioCentury, Recombinant Capital
Rights and permissions
About this article
Cite this article
Lawrence, S. Diagnostics investors think positive. Nat Biotechnol 24, 884 (2006). https://doi.org/10.1038/nbt0806-884
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-884
